Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Candidate malaria vaccines have failed to elicit consistently protective immune responses against challenge with Plasmodium falciparum. NYVAC-Pf7, a highly attenuated vaccinia virus with 7 P. falciparum genes inserted into its genome, was tested in a phase I/IIa safety, immunogenicity, and efficacy vaccine trial in human volunteers. Malaria genes inserted into the NYVAC genome encoded proteins from all stages of the parasite's life cycle. Volunteers received three immunizations of two different dosages of NYVAC-Pf7. The vaccine was safe and well tolerated but variably immunogenic. While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers. Of the 35 volunteers challenged with the bite of 5 P. falciparum-infected Anopheles mosquitoes, 1 was completely protected, and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.

Original publication

DOI

10.1086/515331

Type

Journal article

Journal

J Infect Dis

Publication Date

06/1998

Volume

177

Pages

1664 - 1673

Keywords

Adolescent, Adult, Amino Acid Sequence, Antibodies, Protozoan, Antigens, Protozoan, Consumer Product Safety, Female, Genetic Vectors, Humans, Malaria Vaccines, Male, Middle Aged, Molecular Sequence Data, T-Lymphocytes, Cytotoxic, Vaccines, Attenuated, Vaccines, Synthetic, Vaccinia virus, Viral Proteins, Viral Vaccines